Dr Reddy's announces commercial launch of DRDO's anti-COVID-19 drug 2DG
By MYBRANDBOOK
Hyderabad-based Dr Reddy’s Laboratory announced the commercial launch of the anti-Covid-19 drug, 2-Deoxy-D-Glucose (2-DG) for hospitalized moderate to severe Covid-19 patients.
The anti-Covid therapeutic application of 2-DG has been jointly developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), and Dr Reddy’s Laboratories.
The drug will be supplied to both Government and private Covid-19 health facilities across India. “ The drugs initially will be available at hospitals across metros and Tier 1 cities and in later course expand coverage to rest of the nation, said a company statement and the maximum selling price has been capped at ₹990, with a discounted rate offered to government institutions, it said.
The government institutions will receive at a subsidized rate. Satish Reddy, Chairman, Dr. Reddy’s in the official statement said that 2-DG is another addition to the company’s existing COVID-19 treatment portfolio for mild to moderate and severe conditions and includes a vaccine.
Dr Reddy’s has signed an agreement to distribute Russia’s Covid-19 vaccine Sputnik V in partnership with Snowman Logistics. The Defense Minister, Rajnath Singh had earlier announced that he would personally honour the scientists who played a critical role in the development of the drug as they deserve credit for this achievement.
As per the sources, 2-DG, made of the generic molecule along with an analogue of glucose, accumulates in the virus-infected cells of the body and prevents the invasion of the virus from one cell to another. Viral synthesis and energy production of the virus is cut short stopping it to grow faster helping Covid patients to no longer depend on supplemental oxygen and recover faster.
Initial trials for the drug were conducted between May and October last year at 110 patients at six hospitals. The final phase of the clinical trials was concluded in March 2021 on 220 patients at 27 Covid hospitals. The data from the 2-DG trials suggested the drug usage was safe and Covid-19 patients showed significant recovery.
BHIM to join e-commerce, competing with PhonePe and Google Pay
The government-supported payment software BHIM is getting ready to join t...
The latest version of X helps prevent deepfakes on social medi
To combat deepfakes and shallowfakes, Elon Musk revealed a new update t...
India and Namibia collaborate on a payment system similar to U
Once operational, the platform will enable digital transactions in Namibia,...
Sebi issues show-cause notices to six Adani group firms
Sebi issued show-cause notices to six Adani Group firms, including Adani ...
MICROTEK INTERNATIONAL PVT. LTD.
INFOSYS TECHNOLOGIES PVT. LTD.
WIPRO LTD.
SAFE SECURITY SERVICES PVT. LTD.
Technology Icons Of India 2023: Deepinder Goyal
Deepinder Goyal is the Founder and CEO of Zomato. Deepinder, or Deepi,...
Technology Icons Of India 2023: Ashwini Vaishnaw
Ashwini Vaishnaw is an Indian politician and former IAS officer and is...
Technology Icons Of India 2023: Honorary Prof. N. Balakrishnan
Prof. N. Balakrishnan is an Indian aerospace and computer scientist. H...
STPI encouraging software exports from India
Software Technology Parks of India (STPI) is an S&T organization under...
GeM maintains transparency in online procurement of goods & services
Created in a record time of five months, Government eMarketplace is a ...
NIC bridging the digital divide and supporting government in eGovernance
The National Informatics Centre (NIC) is an Indian government departme...
EXCLUSIVE NETWORKS SALES INDIA PVT. LTD.
Exclusive Networks is a globally trusted cybersecurity specialist hel...
INTEGRA MICRO SYSTEMS PVT. LTD.
Integra is a leading provider of innovative hi-technology products an...
BEETEL TELETECH LTD.
: Beetel is one of the oldest and most reputed brands in the Industry,...